Table 2.

Drugs, studies, and populations

Drug	Study	Population
Atezolizumab	1. NCT03125928 (phase IIA) 2. NCT02605915 (nonrandomized phase Ib study) 3. NCT03417544 (single-arm phase II study) 4. NCT03595592 (randomized phase III interventional clinical trial) 5. NCT02924883 (randomized, multicenter, double-blind, placebo-controlled phase II) 6. NCT03650348 (phase Ib, open-label, dose escalation study) 7. NCT03199885 (randomized, double-blind phase III trial)	1. HER2-positive metastatic breast cancer 2. Metastatic breast cancer 3. HER2-positive metastatic breast cancer, central nervous system metastases 4. Neoadjuvant HER2-positive early high-risk and locally advanced breast cancer (APTneo) 5. HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab and taxane-based therapy 6. HER2-positive advanced or metastatic solid tumors; breast, gastric, bladder, solid tumors 7. First-line HER2-positive metastatic breast cancer
Pembrolizumab	1. PANACEA NCT02129556 (randomized phase Ib/II [16])	1. Metastatic breast cancer, central nervous system after local treatment included
	2. NCT03032107 (phase Ib study)	2. Metastatic breast cancer
Durvalumab	1. NCT02649686 (randomized phase Ib/II [21])	1. HER2-positive metastatic breast cancer
	2. NCT02403271 (phase Ib/II multicenter study)	2. Non-small cell lung cancer, breast cancer, pancreatic cancer
Avelumab	AVIATOR study (NCT03414658 randomized phase II trial)	Patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab and pertuzumab